摘要
目的:研究酪酸梭菌二联活菌散联合重组人干扰素α-2b喷雾剂对轮状病毒性肠炎(Rotavirusenteritis,RVE)患儿肠黏膜屏障功能及T细胞亚群水平的影响。方法:回顾性分析我院2020年1月至2022年12月收治84例RVE患儿临床资料,依照治疗方案不同分为联合组、对照组,每组各42例。对照组采用1-2泵重组人干扰素α-2b喷雾剂喷涂患处治疗,3次·d^(-1);联合组基于对照组加用酪酸梭菌二联活菌散0.5g·次-1口服治疗,2次·d^(-1)。两组用药持续3d。比较两组临床疗效、临床症状改善时间,治疗前、治疗3d后,采用流式细胞仪检测并对比T细胞亚群(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平,采用酶联免疫吸附法检测D-乳酸(D-Lactic acid,D-LA)、肠型脂肪酸结合蛋白(Intestinal fatty aid binding protein,I-FABP)、超敏C反应蛋白(hypersensitive C-reactive proteins,hs-CRP)水平,采用鲎试剂偶氮显色基质法检测内毒素(Endotoxin,EXT)水平,统计对比两组治疗期间不良反应发生率。结果:治疗后联合组有效率(97.62%)高于对照组(80.95%)(P<0.05);联合组退热、腹痛消失、止吐、大便性状恢复时间与对照组相比,明显缩短(P<0.05);与治疗前相比,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平升高(P<0.05),血清hs-CRP、D-LA、EXT、I-FABP水平降低(P<0.05),其中联合组改善更为显著(P<0.05);不良反应发生率两组无明显差异(P>0.05)。结论:采用重组人干扰素α-2b喷雾剂联合酪酸梭菌二联活菌散治疗RVE患儿可促进机体恢复、改善临床症状、修复受损肠黏膜、减轻炎症反应。
Objective:To study the effect of clostridium butyricum combined with recombinant human interferon alpha-2b spray on intestinal mucosal barrier function and T cell subsets in children with rotavirus enteritis(RVE).Methods:A retrospective analysis was conducted on the clinical data of 84 children with RVE admitted to our hospital from January 2020 to December 2022.They were divided into a combination group and a control group according to different treatment plans,with 42 cases in each group.The control group was treated with 1-2 pumps of recombinant human interferon alpha-2b spray applied to the affected area,3 times a day;the combination group was treated with clostridium butyricum bifidobacterium powder 0.5g per time orally,based on the control group,plus twice a day.Both groups continued the medication for 3 days.The clinical efficacy and improvement time of clinical symptoms were compared between the two groups.Before and 3 days after treatment,the levels of T-cell subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))were detected and compared using flow cytometry,the levels of D-lactic acid(D-LA),intestinal fatty acid binding protein(I-FABP),and hypersensitive C-reactive protein(hs-CRP)were measured using enzyme-linked immunosorbent assay(ELISA),the endotoxin(EXT)level was measured using the limulus amebocyte lysate(LAL)method,and the incidence of adverse reactions during the treatment period was statistically compared between the two groups.Results:After treatment,the effective rate of the combined group(97.62%)was higher than that of the control group(80.95%)(P<0.05);compared with the control group,the recovery time of fever,abdominal pain,vomiting and stool traits in the combined group were significantly shorter(P<0.05);compared with before treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the two groups increased(P<0.05),and the levels of serum hs-CRP,D-LA,EXT and I-FABP in the two groups decreased(P<0.05),especially in the combined group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Recombinant human interferonα-2b spray combined with Clostridium butyricum bi-living bacteria powder live powder in the treatment of children with RVE can promote the recovery of the body,improve the clinical symptoms,repair the damaged intestinal mucosa,reduce the inflammatory reaction,and has certain safety.
作者
王伟
李娜
任淑红
Wang Wei;Li Na;Ren Shu-hong(Zhengzhou First People's Hospital Pediatrics,Zhengzhou 450000,China;Department of Pediatrics,Yulin Hospital,The First Affiliated Hospital of Xi'an Jiaotong University,Yulin 719000,Shanxi,China)
关键词
重组人干扰素Α-2B喷雾剂
酪酸梭菌二联活菌散
轮状病毒性肠炎
不良反应
Recombinant human interferonα-2b spray
Clostridium butyricum bi-living bacteria powder
Rotavirus enteritis
Adverse reactions
